Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.

× No keyword cloud information.

22 in total

1. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.

Authors: S H Chao; K Fujinaga; J E Marion; R Taube; E A Sausville; A M Senderowicz; B M Peterlin; D H Price
Journal: J Biol Chem Date: 2000-09-15 Impact factor: 5.157

2. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.

Authors: Ivana Gojo; Bin Zhang; Robert G Fenton
Journal: Clin Cancer Res Date: 2002-11 Impact factor: 12.531

Review 3. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.

Authors: A M Senderowicz
Journal: Invest New Drugs Date: 1999 Impact factor: 3.850

4. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.

Authors: William Blum; Mitch A Phelps; Rebecca B Klisovic; Darlene M Rozewski; Wenjun Ni; Katie A Albanese; Brad Rovin; Cheryl Kefauver; Steven M Devine; David M Lucas; Amy Johnson; Larry J Schaaf; John C Byrd; Guido Marcucci; Michael R Grever
Journal: Haematologica Date: 2010-05-11 Impact factor: 9.941

Review 5. The proteasome: a novel target for cancer chemotherapy.

Authors: J B Almond; G M Cohen
Journal: Leukemia Date: 2002-04 Impact factor: 11.528

6. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.

Authors: L Cartee; Z Wang; R H Decker; S P Chellappan; G Fusaro; K G Hirsch; H M Sankala; P Dent; S Grant
Journal: Cancer Res Date: 2001-03-15 Impact factor: 12.701

7. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors: B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245

8. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Authors: C Tom Kouroukis; Andrew Belch; Michael Crump; Elizabeth Eisenhauer; Randy D Gascoyne; Ralph Meyer; Reinhard Lohmann; Pedro Lopez; Jean Powers; Robert Turner; Joseph M Connors
Journal: J Clin Oncol Date: 2003-05-01 Impact factor: 44.544

9. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.

Authors: Yi-He Ling; Leonard Liebes; Bruce Ng; Michael Buckley; Peter J Elliott; Julian Adams; Jian-Dong Jiang; Franco M Muggia; Roman Perez-Soler
Journal: Mol Cancer Ther Date: 2002-08 Impact factor: 6.261

Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.